As cancer rates rise globally, highly effective, safe, patient-centric treatment options are more critical. The EvaThera Theranostics platform of Molecular Targeting Technologies, Inc. contains a new generation of Evans Blue-based radiopharmaceuticals with strong affinity for albumin which: Extend the blood half-life of the targeting radiopeptides Decrease their blood clearance and improve uptake with less toxicity Promise improved therapeutic and diagnostic outcomes in SSTR2 and integrin expressing cancer patients. Therapeutics targeting SST receptor subtype 2 (SSTR-2) protein expressing tumors, like Neuroendocrine Tumors (NETs) and Hurthle cell thyroid cancer, show comparatively low response rates, due in part to rapid blood clearance and cautious dosing to avoid potential renal toxicity. EBTATE (177Lu-DOTA-EB-TATE) is a long-acting somatostatin analogue, an innovative three-in-one therapeutic, composed of a targeting octreotate peptide, modified Evans blue dye to improve biodistribution and chelator carrying a tumor killing radionuclide (177Lu). Trial results show improved safety and efficacy with fewer, lower doses than competing treatments with objective responses achieved after a single injection. EBRGD is an Evans Blue modified RGD 177Lu peptide targeting integrin v3. It was developed to treat integrin expressing cancers like Glioblastoma Multiforme (GBM) and Non-Small Cell Lung Cancer (NSCLC). Today, there are 17,000 new US GBM diagnoses annually with median survival of only 15-16 months post-surgery. Prolonged circulation half-life delivers good, highly targeted tumor uptake of a diagnostic 64Cu EBRGD in a GBM human trial, holding out promise for a 177Lu therapeutic. Preclinical studies with 177Lu-EBRGD in tandem with a PD-L1 checkpoint inhibitor immunotherapy show significant synergy in decreased colorectal tumor volume and extended survival.